Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIMNYSE:IKTNYSE:PRMENASDAQ:PRVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$9.21+11.0%$9.13$0.06▼$14.93$665.79M0.76572,650 shs87,143 shsIKTInhibikase Therapeutics$1.66-2.4%$1.99$1.12▼$4.20$123.41M0.94241,800 shs278,054 shsPRMEPrime Medicine$2.07+15.0%$1.45$1.11▼$6.75$271.78M1.551.43 million shs5.92 million shsPRVLPrevail Therapeutics$23.00$23.01$9.02▼$23.35$787.66M1.59955,800 shsN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech0.00%-9.19%-9.19%-41.55%-79.11%IKTInhibikase Therapeutics0.00%-10.99%-14.57%-28.27%+14.09%PRMEPrime Medicine0.00%+23.29%+53.19%-7.69%-71.34%PRVLPrevail Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMAIM ImmunoTech1.8423 of 5 stars3.50.00.00.02.31.70.0IKTInhibikase Therapeutics1.4721 of 5 stars3.31.00.00.00.00.01.3PRMEPrime Medicine3.8402 of 5 stars4.41.00.00.03.35.00.6PRVLPrevail TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$275.002,885.88% UpsideIKTInhibikase Therapeutics 2.50Moderate Buy$6.50291.57% UpsidePRMEPrime Medicine 2.75Moderate Buy$10.08387.12% UpsidePRVLPrevail Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PRVL, AIM, PRME, and IKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025PRMEPrime MedicineCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $1.505/20/2025PRMEPrime MedicineJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.005/20/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/20/2025PRMEPrime MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral5/19/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.003/28/2025IKTInhibikase TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/20/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $16.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$170K3,916.42N/AN/A$0.20 per share46.05IKTInhibikase Therapeutics$260K474.65N/AN/A$1.78 per share0.93PRMEPrime Medicine$3.85M70.67N/AN/A$1.37 per share1.51PRVLPrevail TherapeuticsN/AN/AN/AN/A$4.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$0.31N/AN/AN/A-12,594.21%-421.73%-147.54%N/AIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/APRMEPrime Medicine-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/APRVLPrevail Therapeutics-$63.19M-$2.22N/AN/AN/AN/A-55.57%-48.14%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/APRMEPrime Medicine$1.4569.86%N/AN/A N/APRVLPrevail TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75IKTInhibikase TherapeuticsN/A0.850.85PRMEPrime MedicineN/A6.506.50PRVLPrevail TherapeuticsN/A7.567.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%IKTInhibikase Therapeutics3.81%PRMEPrime Medicine70.37%PRVLPrevail Therapeutics86.80%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%IKTInhibikase Therapeutics7.30%PRMEPrime Medicine22.93%PRVLPrevail Therapeutics57.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech2072.29 million68.74 millionNot OptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionablePRMEPrime Medicine234131.29 million100.38 millionOptionablePRVLPrevail Therapeutics6634.25 millionN/ANot OptionablePRVL, AIM, PRME, and IKT HeadlinesRecent News About These CompaniesPrevail, Inc. receives $120K grant from Hamilton County Community FoundationMay 29, 2025 | readthereporter.comI Prevail Announce Split With Co-Vocalist Brian Burkheiser in New StatementMay 16, 2025 | msn.comPrevail Bank donates to 29 charitable programsApril 29, 2025 | wausaupilotandreview.comLeawood-based Prevail launches $100M VC fund, makes first two investmentsApril 9, 2025 | bizjournals.comData supports Medtronic Prevail paclitaxel-coated balloonMarch 10, 2025 | massdevice.comPrevail Bank’s matching funds campaign garners more than $20KDecember 30, 2024 | wausaupilotandreview.comPrevail provides holiday hope to 55 families who need it mostDecember 24, 2024 | msn.comPrevail receives $10,000 gift from Elements CaresDecember 11, 2024 | readthereporter.comI Prevail + Hollywood Undead SCREAM Through Haunted Blood Prison | Paranormal PrisonNovember 13, 2024 | msn.comPrevail Bank launches Holiday Matching Funds campaignNovember 7, 2024 | centralwinews.comHow I Prevail and All Time Low teamed up to create their monster hit “Hate This Song”November 4, 2024 | yahoo.comPrevail Endowment receives $1M gift honoring Frank Pichler’s LegacyNovember 1, 2024 | readthereporter.comIllinois Takes on the Ducks: Will Toughness Prevail?October 25, 2024 | msn.comMedtronic’s Prevail DCB pivotal trial receives FDA IDE approvalOctober 25, 2024 | msn.comFDA approves IDE for Medtronic Prevail drug-coated balloonOctober 23, 2024 | massdevice.comPasto Italiano goes Purple for PrevailOctober 21, 2024 | readthereporter.comSlaughter to Prevail’s Epic New Song ‘Behelit’ Has Fans Reacting to Different StyleOctober 16, 2024 | msn.comInto A Third Future in Sparking Zero, Unlock The Three Prevail PathOctober 14, 2024 | gamepressure.comLiberty vs. Aces Series Analysis: Who Will Prevail?October 4, 2024 | msn.comComo’s ‘May Peace Prevail on Earth’ building stands tallSeptember 30, 2024 | mndaily.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAlphabet Enters a Bull Market: Is It Time to Buy?By Ryan Hasson | June 14, 2025View Alphabet Enters a Bull Market: Is It Time to Buy?Target's Big Bet: Is It a Cheap Stock or a Value Trap? By Jeffrey Neal Johnson | May 29, 2025View Target's Big Bet: Is It a Cheap Stock or a Value Trap? Will Warner Bros. Discovery’s Split Produce Double the Upside?By Jeffrey Neal Johnson | June 11, 2025View Will Warner Bros. Discovery’s Split Produce Double the Upside?MongoDB Affirms Outlook and Accelerates Stock Price ReversalBy Thomas Hughes | June 6, 2025View MongoDB Affirms Outlook and Accelerates Stock Price ReversalPRVL, AIM, PRME, and IKT Company DescriptionsAIM ImmunoTech NYSE:AIM$9.21 +0.91 (+10.96%) Closing price 04:00 PM EasternExtended Trading$9.69 +0.48 (+5.22%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Inhibikase Therapeutics NYSE:IKT$1.66 -0.04 (-2.35%) Closing price 04:00 PM EasternExtended Trading$1.67 +0.01 (+0.60%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Prime Medicine NYSE:PRME$2.07 +0.27 (+15.00%) Closing price 04:00 PM EasternExtended Trading$2.08 +0.02 (+0.72%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.Prevail Therapeutics NASDAQ:PRVLPrevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
